Bank of New York Mellon Corp Makes New Investment in Metsera Inc. (NASDAQ:MTSR)

Key Points

• Bank of New York Mellon Corp acquired a new stake in Metsera Inc., purchasing 32,494 shares valued at approximately $884,000.
• Metsera's stock rose by 5.8%, currently priced at $34.89, with a 52-week range between $12.30 and $47.40.
• Analysts maintain a consensus rating of "Buy" for Metsera, with price targets reaching as high as $65.00.

Bank of New York Mellon Corp purchased a new position in shares of Metsera Inc. (NASDAQ:MTSR - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 32,494 shares of the company's stock, valued at approximately $884,000.

Metsera Stock Down 1.3%

Shares of MTSR stock traded down $0.42 during trading on Wednesday, reaching $32.93. The company's stock had a trading volume of 856,854 shares, compared to its average volume of 958,466. The firm's fifty day moving average is $32.85. Metsera Inc. has a one year low of $12.30 and a one year high of $47.40.

Metsera (NASDAQ:MTSR - Get Free Report) last announced its quarterly earnings data on Monday, July 28th. The company reported ($0.66) EPS for the quarter.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on MTSR. Guggenheim boosted their price objective on shares of Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a report on Tuesday, June 10th. Wells Fargo & Company initiated coverage on shares of Metsera in a report on Friday, June 20th. They issued an "overweight" rating and a $65.00 price target for the company. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Metsera presently has an average rating of "Buy" and an average target price of $55.00.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.